Orchid Pharma Limited (ORCHPHARMA) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE191A01027
Key metrics
- Market Cap
- ₹4,948 Cr
- P/E Ratio
- 163.97
- EPS
- 5.95
- Book Value
- 253.91
- P/B Ratio
- 3.67
- ROE
- 1.6%
- ROCE
- 9.61%
- Debt / Equity
- 0.28
- Net Margin
- 2.53%
- Revenue Growth
- -12%
- Profit Growth
- -79.38%
- Dividend Yield
- —
- 52W High
- ₹1,133.00
- 52W Low
- ₹480.00
- Market Cap Band
- small cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
- Headquarters
- Chennai, India
- Promoter Holding
- 59.15%
The full Orchid Pharma Limited analysis
Create a free account to open the complete ORCHPHARMA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.